Cytosorbents (CTSO) vs DarioHealth (DRIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cytosorbents (CTSO) has outperformed DarioHealth (DRIO) over the past year, losing 70.6% versus a loss of 90.5%. Over five years, CTSO leads with a -95.6% price change compared with -99.6% for DRIO. DarioHealth is the larger company by market cap ($14.9 million vs $13.1 million), about 1.1 times the size, while Cytosorbents is growing revenue faster (+4.1% vs -17.3%).
Cytosorbents converts more of its revenue into profit, with a net margin of -22.1% versus -186.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTSO | DRIO |
|---|---|---|
| Share price | $4.16 | $1.32 |
| Market cap | $13.12M | $14.90M |
| 1-day change | -18.91% | -8.33% |
| YTD return | -67.45% | -88.40% |
| 1-year return | -70.58% | -90.51% |
| 5-year return | -95.62% | -99.58% |
| EPS (TTM) | $-5.62 | $-3.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $37.06M | $22.36M |
| Revenue growth (YoY) | +4.12% | -17.31% |
| Net income (latest FY) | $-8.20M | $-41.71M |
| Gross margin | 71.48% | 56.64% |
| Operating margin | -39.79% | -163.94% |
| Net margin | -22.12% | -186.56% |
| 52-week high | $17.00 | $14.49 |
| 52-week low | $2.84 | $1.09 |
| Distance from 52-week high | -75.53% | -90.89% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1041.83% | +930.30% |
| Average volume | 37.34K | 48.52K |
| Shares outstanding | 3.15M | 11.29M |
| Employees | 129 | 160 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTSO has outperformed DRIO by 19.9 percentage points over the past year.
- Cytosorbents is more profitable, keeping -22.1 cents of every revenue dollar as net income versus -186.6 cents for DarioHealth.
- Cytosorbents grew revenue faster in its latest fiscal year (+4.12% vs -17.31%).
About Cytosorbents
CTSO stock →Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
Health Care · Medical/Dental Instruments · 129 employees
About DarioHealth
DRIO stock →DarioHealth Corp. operates as a digital health company in the United States and internationally.
Health Care · Medical/Dental Instruments · 160 employees
CTSO vs DRIO FAQ
Which is bigger, Cytosorbents or DarioHealth?
DarioHealth (DRIO) is larger, with a market capitalization of $14.90M compared with $13.12M for Cytosorbents (CTSO).
Which stock has performed better over the past year, CTSO or DRIO?
CTSO returned -70.58% over the past 12 months, compared with -90.51% for DRIO (price return, excluding dividends). Past performance does not predict future results.
Are Cytosorbents and DarioHealth in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.